Latest Breaking News On - Protac protein degrader - Page 1 : comparemela.com

Vepdegestrant has received FDA fast track designation for select patients with ER-positive/HER2-negative locally advanced or metastatic breast cancer.

United statesSan antonioJohn houstonArvinas incPfizer incAntonio breast cancer symposiumHuman epidermal growthFda fast track designationPatients with er positive her2 negative locally advanced or metastatic breast cancerProtac protein degraderPhase 1 2 veritac study